메뉴 건너뛰기




Volumn 12, Issue 2, 2015, Pages 87-95

Assays for predicting and monitoring responses to lung cancer immunotherapy

Author keywords

Antibody; Immunotherapy; Lung cancer; PD 1 ligand (PD L1); Programmed cell death 1 (PD 1)

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR;

EID: 84937544496     PISSN: 20953941     EISSN: None     Source Type: Journal    
DOI: 10.7497/j.issn.2095-3941.2015.0019     Document Type: Review
Times cited : (41)

References (76)
  • 2
    • 0017076849 scopus 로고
    • Oat cell carcinoma of the lung. Early treatment results of combination radiation therapy and chemotherapy
    • Hornback NB, Einhorn L, Shidnia H, Joe BT, Krause M, Furnas B. Oat cell carcinoma of the lung. Early treatment results of combination radiation therapy and chemotherapy. Cancer 1976;37:2658-2664.
    • (1976) Cancer , vol.37 , pp. 2658-2664
    • Hornback, N.B.1    Einhorn, L.2    Shidnia, H.3    Joe, B.T.4    Krause, M.5    Furnas, B.6
  • 3
  • 4
    • 0036843105 scopus 로고    scopus 로고
    • Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer
    • Scagliotti GV, De Marinis F, Rinaldi M, Crinò L, Gridelli C, Ricci S, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002;20:4285-4291.
    • (2002) J Clin Oncol , vol.20 , pp. 4285-4291
    • Scagliotti, G.V.1    De Marinis, F.2    Rinaldi, M.3    Crinò, L.4    Gridelli, C.5    Ricci, S.6
  • 5
    • 33845490014 scopus 로고    scopus 로고
    • Paclitaxel-carboplatin alone or with bevacizumab for non-smallcell lung cancer
    • Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-smallcell lung cancer. N Engl J Med 2006;355:2542-2550.
    • (2006) N Engl J Med , vol.355 , pp. 2542-2550
    • Sandler, A.1    Gray, R.2    Perry, M.C.3    Brahmer, J.4    Schiller, J.H.5    Dowlati, A.6
  • 6
    • 33747847740 scopus 로고    scopus 로고
    • Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IBIIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial
    • Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzáles-Larriba JL, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IBIIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006;7:719-727.
    • (2006) Lancet Oncol , vol.7 , pp. 719-727
    • Douillard, J.Y.1    Rosell, R.2    De Lena, M.3    Carpagnano, F.4    Ramlau, R.5    Gonzáles-Larriba, J.L.6
  • 7
    • 33846794665 scopus 로고    scopus 로고
    • A systematic review and meta-analysis of the literature: chemotherapy and surgery versus surgery alone in non-small cell lung cancer
    • Burdett S, Stewart LA, Rydzewska L. A systematic review and meta-analysis of the literature: chemotherapy and surgery versus surgery alone in non-small cell lung cancer. J Thorac Oncol 2006;1:611-621.
    • (2006) J Thorac Oncol , vol.1 , pp. 611-621
    • Burdett, S.1    Stewart, L.A.2    Rydzewska, L.3
  • 8
    • 49049089802 scopus 로고    scopus 로고
    • Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer
    • Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-3551.
    • (2008) J Clin Oncol , vol.26 , pp. 3543-3551
    • Scagliotti, G.V.1    Parikh, P.2    Von Pawel, J.3    Biesma, B.4    Vansteenkiste, J.5    Manegold, C.6
  • 9
    • 15744362912 scopus 로고    scopus 로고
    • The 2004 World Health Organization classification of lung tumors
    • Beasley MB, Brambilla E, Travis WD. The 2004 World Health Organization classification of lung tumors. Semin Roentgenol 2005;40:90-97.
    • (2005) Semin Roentgenol , vol.40 , pp. 90-97
    • Beasley, M.B.1    Brambilla, E.2    Travis, W.D.3
  • 10
    • 84875925170 scopus 로고    scopus 로고
    • New pathologic classification of lung cancer: relevance for clinical practice and clinical trials
    • Travis WD, Brambilla E, Riely GJ. New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. J Clin Oncol 2013;31:992-1001.
    • (2013) J Clin Oncol , vol.31 , pp. 992-1001
    • Travis, W.D.1    Brambilla, E.2    Riely, G.J.3
  • 11
    • 0017287037 scopus 로고
    • Regional immunotherapy of lung cancer with intrapleural B.C.G
    • McKneally MF, Maver C, Kausel HW. Regional immunotherapy of lung cancer with intrapleural B.C.G. Lancet 1976;1:377-379.
    • (1976) Lancet , vol.1 , pp. 377-379
    • McKneally, M.F.1    Maver, C.2    Kausel, H.W.3
  • 12
    • 0019985540 scopus 로고
    • Regional immunotherapy in resectable squamous cell lung carcinoma. Analysis of a randomized study
    • Roeslin N, Lang JM, Morand G, Wihlm JM, Witz JP. Regional immunotherapy in resectable squamous cell lung carcinoma. Analysis of a randomized study. Cancer Immunol Immunother 1982;13:174-175.
    • (1982) Cancer Immunol Immunother , vol.13 , pp. 174-175
    • Roeslin, N.1    Lang, J.M.2    Morand, G.3    Wihlm, J.M.4    Witz, J.P.5
  • 13
    • 84904112296 scopus 로고    scopus 로고
    • Immunotherapy in the treatment of non-small cell lung cancer
    • Sundar R, Soong R, Cho BC, Brahmer JR, Soo RA. Immunotherapy in the treatment of non-small cell lung cancer. Lung Cancer 2014;85:101-109.
    • (2014) Lung Cancer , vol.85 , pp. 101-109
    • Sundar, R.1    Soong, R.2    Cho, B.C.3    Brahmer, J.R.4    Soo, R.A.5
  • 14
    • 0021888581 scopus 로고
    • Combined modality therapy with radiotherapy, chemotherapy, and immunotherapy in limited small-cell carcinoma of the lung: a Phase III cancer and Leukemia Group B Study
    • Maurer LH, Pajak T, Eaton W, Comis R, Chahinian P, Faulkner C, et al. Combined modality therapy with radiotherapy, chemotherapy, and immunotherapy in limited small-cell carcinoma of the lung: a Phase III cancer and Leukemia Group B Study. J Clin Oncol 1985;3:969-976.
    • (1985) J Clin Oncol , vol.3 , pp. 969-976
    • Maurer, L.H.1    Pajak, T.2    Eaton, W.3    Comis, R.4    Chahinian, P.5    Faulkner, C.6
  • 15
    • 0022979412 scopus 로고
    • Intratumoral Bacillus Calmette-Guérin immunotherapy prior to surgery for carcinoma of the lung: results of a prospective randomized trial
    • Matthay RA, Mahler DA, Beck GJ, Loke J, Baue AE, Carter DC, et al. Intratumoral Bacillus Calmette-Guérin immunotherapy prior to surgery for carcinoma of the lung: results of a prospective randomized trial. Cancer Res 1986;46:5963-5968.
    • (1986) Cancer Res , vol.46 , pp. 5963-5968
    • Matthay, R.A.1    Mahler, D.A.2    Beck, G.J.3    Loke, J.4    Baue, A.E.5    Carter, D.C.6
  • 17
    • 0028926389 scopus 로고
    • Concomitant administration of interleukin-2 plus tumor necrosis factor in advanced non-small cell lung cancer
    • Schiller JH, Morgan-Ihrig C, Levitt ML. Concomitant administration of interleukin-2 plus tumor necrosis factor in advanced non-small cell lung cancer. Am J Clin Oncol 1995;18:47-51.
    • (1995) Am J Clin Oncol , vol.18 , pp. 47-51
    • Schiller, J.H.1    Morgan-Ihrig, C.2    Levitt, M.L.3
  • 18
    • 1542360632 scopus 로고    scopus 로고
    • Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial
    • Lara PN Jr, Laptalo L, Longmate J, Lau DH, Gandour-Edwards R, Gumerlock PH, et al. Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial. Clin Lung Cancer 2004;5:231-236.
    • (2004) Clin Lung Cancer , vol.5 , pp. 231-236
    • Lara, P.N.1    Laptalo, L.2    Longmate, J.3    Lau, D.H.4    Gandour-Edwards, R.5    Gumerlock, P.H.6
  • 19
    • 16844375982 scopus 로고    scopus 로고
    • Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of Cancer and Leukemia Group B
    • Clamon G, Herndon J, Kern J, Govindan R, Garst J, Watson D, et al. Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of Cancer and Leukemia Group B. Cancer. 2005;103:1670-1675.
    • (2005) Cancer , vol.103 , pp. 1670-1675
    • Clamon, G.1    Herndon, J.2    Kern, J.3    Govindan, R.4    Garst, J.5    Watson, D.6
  • 20
    • 84892485531 scopus 로고    scopus 로고
    • Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer
    • Brahmer JR, Pardoll DM. Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer. Cancer Immunol Res. 2013;1:85-91.
    • (2013) Cancer Immunol Res , vol.1 , pp. 85-91
    • Brahmer, J.R.1    Pardoll, D.M.2
  • 22
    • 44349150012 scopus 로고    scopus 로고
    • Inhibitory B7-family molecules in the tumour microenvironment
    • Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 2008;8:467-477.
    • (2008) Nat Rev Immunol , vol.8 , pp. 467-477
    • Zou, W.1    Chen, L.2
  • 23
    • 84858766182 scopus 로고    scopus 로고
    • The blockade of immune checkpoints in cancer immunotherapy
    • Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-264.
    • (2012) Nat Rev Cancer , vol.12 , pp. 252-264
    • Pardoll, D.M.1
  • 24
    • 84890980389 scopus 로고    scopus 로고
    • Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer
    • Drake CG, Lipson EJ, Brahmer JR. Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol 2014;11:24-37.
    • (2014) Nat Rev Clin Oncol , vol.11 , pp. 24-37
    • Drake, C.G.1    Lipson, E.J.2    Brahmer, J.R.3
  • 25
    • 0026700235 scopus 로고
    • Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death
    • Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1992;11:3887-3895.
    • (1992) EMBO J , vol.11 , pp. 3887-3895
    • Ishida, Y.1    Agata, Y.2    Shibahara, K.3    Honjo, T.4
  • 28
  • 29
    • 33947407689 scopus 로고    scopus 로고
    • Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression
    • Radziewicz H, Ibegbu CC, Fernandez ML, Workowski KA, Obideen K, Wehbi M, et al. Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression. J Virol 2007;81:2545-2553.
    • (2007) J Virol , vol.81 , pp. 2545-2553
    • Radziewicz, H.1    Ibegbu, C.C.2    Fernandez, M.L.3    Workowski, K.A.4    Obideen, K.5    Wehbi, M.6
  • 31
    • 0032736029 scopus 로고    scopus 로고
    • B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion
    • Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999;5:1365-1369.
    • (1999) Nat Med , vol.5 , pp. 1365-1369
    • Dong, H.1    Zhu, G.2    Tamada, K.3    Chen, L.4
  • 33
    • 84879579673 scopus 로고    scopus 로고
    • At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy
    • Intlekofer AM, Thompson CB. At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. J Leukoc Biol 2013;94:25-39.
    • (2013) J Leukoc Biol , vol.94 , pp. 25-39
    • Intlekofer, A.M.1    Thompson, C.B.2
  • 35
    • 34247884612 scopus 로고    scopus 로고
    • The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection
    • Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol 2007;8:239-245.
    • (2007) Nat Immunol , vol.8 , pp. 239-245
    • Sharpe, A.H.1    Wherry, E.J.2    Ahmed, R.3    Freeman, G.J.4
  • 37
    • 33846118474 scopus 로고    scopus 로고
    • Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
    • Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ, et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 2007;13:84-88.
    • (2007) Nat Med , vol.13 , pp. 84-88
    • Parsa, A.T.1    Waldron, J.S.2    Panner, A.3    Crane, C.A.4    Parney, I.F.5    Barry, J.J.6
  • 38
    • 79952202494 scopus 로고    scopus 로고
    • Cisplatin induces programmed death-1-ligand 1(PD-L1) over-expression in hepatoma H22 cells via Erk /MAPK signaling pathway
    • Qin X, Liu C, Zhou Y, Wang G. Cisplatin induces programmed death-1-ligand 1(PD-L1) over-expression in hepatoma H22 cells via Erk /MAPK signaling pathway. Cell Mol Biol (Noisy-le-grand) 2010;56 Suppl:OL1366-OL1372.
    • (2010) Cell Mol Biol (Noisy-le-grand) , vol.56 , pp. OL1366-OL1372
    • Qin, X.1    Liu, C.2    Zhou, Y.3    Wang, G.4
  • 39
    • 58549102319 scopus 로고    scopus 로고
    • Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7- H1)
    • Marzec M, Zhang Q, Goradia A, Raghunath PN, Liu X, Paessler M, et al. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7- H1). Proc Natl Acad Sci U S A 2008;105:20852-20857.
    • (2008) Proc Natl Acad Sci U S A , vol.105 , pp. 20852-20857
    • Marzec, M.1    Zhang, Q.2    Goradia, A.3    Raghunath, P.N.4    Liu, X.5    Paessler, M.6
  • 40
    • 77953747963 scopus 로고    scopus 로고
    • The PD-1 pathway in tolerance and autoimmunity
    • Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 2010;236:219-242.
    • (2010) Immunol Rev , vol.236 , pp. 219-242
    • Francisco, L.M.1    Sage, P.T.2    Sharpe, A.H.3
  • 41
    • 34347400169 scopus 로고    scopus 로고
    • Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway
    • Liu J, Hamrouni A, Wolowiec D, Coiteux V, Kuliczkowski K, Hetuin D, et al. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood 2007;110:296-304.
    • (2007) Blood , vol.110 , pp. 296-304
    • Liu, J.1    Hamrouni, A.2    Wolowiec, D.3    Coiteux, V.4    Kuliczkowski, K.5    Hetuin, D.6
  • 42
    • 31444451661 scopus 로고    scopus 로고
    • Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274)
    • Lee SJ, Jang BC, Lee SW, Yang YI, Suh SI, Park YM, et al. Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274). FEBS Lett 2006;580:755-762.
    • (2006) FEBS Lett , vol.580 , pp. 755-762
    • Lee, S.J.1    Jang, B.C.2    Lee, S.W.3    Yang, Y.I.4    Suh, S.I.5    Park, Y.M.6
  • 43
    • 84859128199 scopus 로고    scopus 로고
    • Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape
    • 127ra137.
    • Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012;4:127ra137.
    • (2012) Sci Transl Med , vol.4
    • Taube, J.M.1    Anders, R.A.2    Young, G.D.3    Xu, H.4    Sharma, R.5    McMiller, T.L.6
  • 44
    • 18544380239 scopus 로고    scopus 로고
    • Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion
    • Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002;8:793-800.
    • (2002) Nat Med , vol.8 , pp. 793-800
    • Dong, H.1    Strome, S.E.2    Salomao, D.R.3    Tamura, H.4    Hirano, F.5    Flies, D.B.6
  • 45
    • 0038273853 scopus 로고    scopus 로고
    • Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
    • Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 2003;9:562-567.
    • (2003) Nat Med , vol.9 , pp. 562-567
    • Curiel, T.J.1    Wei, S.2    Dong, H.3    Alvarez, X.4    Cheng, P.5    Mottram, P.6
  • 46
    • 33745491116 scopus 로고    scopus 로고
    • Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance
    • Wu C, Zhu Y, Jiang J, Zhao J, Zhang XG, Xu N. Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem 2006;108:19-24.
    • (2006) Acta Histochem , vol.108 , pp. 19-24
    • Wu, C.1    Zhu, Y.2    Jiang, J.3    Zhao, J.4    Zhang, X.G.5    Xu, N.6
  • 47
    • 33846852187 scopus 로고    scopus 로고
    • Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy
    • Thompson RH, Dong H, Kwon ED. Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy. Clin Cancer Res 2007;13:709s-715s.
    • (2007) Clin Cancer Res , vol.13 , pp. 709s-715s
    • Thompson, R.H.1    Dong, H.2    Kwon, E.D.3
  • 48
    • 34247532726 scopus 로고    scopus 로고
    • Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer
    • Nomi T, Sho M, Akahori T, Hamada K, Kubo A, Kanehiro H, et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 2007;13:2151-2157.
    • (2007) Clin Cancer Res , vol.13 , pp. 2151-2157
    • Nomi, T.1    Sho, M.2    Akahori, T.3    Hamada, K.4    Kubo, A.5    Kanehiro, H.6
  • 49
    • 49649114804 scopus 로고    scopus 로고
    • Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies
    • Berger R, Rotem-Yehudar R, Slama G, Landes S, Kneller A, Leiba M, et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 2008;14:3044-3051.
    • (2008) Clin Cancer Res , vol.14 , pp. 3044-3051
    • Berger, R.1    Rotem-Yehudar, R.2    Slama, G.3    Landes, S.4    Kneller, A.5    Leiba, M.6
  • 50
    • 33847611968 scopus 로고    scopus 로고
    • Programmed cell death 1 ligand 1 and tumorinfiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer
    • Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, et al. Programmed cell death 1 ligand 1 and tumorinfiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A 2007;104:3360-3365.
    • (2007) Proc Natl Acad Sci U S A , vol.104 , pp. 3360-3365
    • Hamanishi, J.1    Mandai, M.2    Iwasaki, M.3    Okazaki, T.4    Tanaka, Y.5    Yamaguchi, K.6
  • 51
    • 80052476869 scopus 로고    scopus 로고
    • High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation
    • Mu CY, Huang JA, Chen Y, Chen C, Zhang XG. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol 2011;28:682-688.
    • (2011) Med Oncol , vol.28 , pp. 682-688
    • Mu, C.Y.1    Huang, J.A.2    Chen, Y.3    Chen, C.4    Zhang, X.G.5
  • 52
    • 84871966600 scopus 로고    scopus 로고
    • PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer
    • Badoual C, Hans S, Merillon N, Van Ryswick C, Ravel P, Benhamouda N, et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res 2013;73:128-138.
    • (2013) Cancer Res , vol.73 , pp. 128-138
    • Badoual, C.1    Hans, S.2    Merillon, N.3    Van Ryswick, C.4    Ravel, P.5    Benhamouda, N.6
  • 55
    • 84898476658 scopus 로고    scopus 로고
    • Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA
    • Thierry AR, Mouliere F, El Messaoudi S, Mollevi C, Lopez-Crapez E, Rolet F, et al. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat Med 2014;20:430-435.
    • (2014) Nat Med , vol.20 , pp. 430-435
    • Thierry, A.R.1    Mouliere, F.2    El Messaoudi, S.3    Mollevi, C.4    Lopez-Crapez, E.5    Rolet, F.6
  • 56
    • 84883027282 scopus 로고    scopus 로고
    • Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer
    • Pailler E, Adam J, Barthélémy A, Oulhen M, Auger N, Valent A, et al. Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer. J Clin Oncol 2013;31:2273-2281.
    • (2013) J Clin Oncol , vol.31 , pp. 2273-2281
    • Pailler, E.1    Adam, J.2    Barthélémy, A.3    Oulhen, M.4    Auger, N.5    Valent, A.6
  • 57
    • 84907497893 scopus 로고    scopus 로고
    • High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial
    • Rossille D, Gressier M, Damotte D, Maucort-Boulch D, Pangault C, Semana G, et al. High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial. Leukemia 2014;28:2367-2375.
    • (2014) Leukemia , vol.28 , pp. 2367-2375
    • Rossille, D.1    Gressier, M.2    Damotte, D.3    Maucort-Boulch, D.4    Pangault, C.5    Semana, G.6
  • 58
    • 77954899030 scopus 로고    scopus 로고
    • Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates
    • Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010;28:3167-3175.
    • (2010) J Clin Oncol , vol.28 , pp. 3167-3175
    • Brahmer, J.R.1    Drake, C.G.2    Wollner, I.3    Powderly, J.D.4    Picus, J.5    Sharfman, W.H.6
  • 59
    • 84920655625 scopus 로고    scopus 로고
    • PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients
    • D'Incecco A, Andreozzi M, Ludovini V, Rossi E, Capodanno A, Landi L, et al. PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. Br J Cancer 2015;112:95-102.
    • (2015) Br J Cancer , vol.112 , pp. 95-102
    • D'Incecco, A.1    Andreozzi, M.2    Ludovini, V.3    Rossi, E.4    Capodanno, A.5    Landi, L.6
  • 60
    • 84923078390 scopus 로고    scopus 로고
    • MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
    • Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014;515:558-562.
    • (2014) Nature , vol.515 , pp. 558-562
    • Powles, T.1    Eder, J.P.2    Fine, G.D.3    Braiteh, F.S.4    Loriot, Y.5    Cruz, C.6
  • 61
    • 84920956735 scopus 로고    scopus 로고
    • Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
    • Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014;515:563-567.
    • (2014) Nature , vol.515 , pp. 563-567
    • Herbst, R.S.1    Soria, J.C.2    Kowanetz, M.3    Fine, G.D.4    Hamid, O.5    Gordon, M.S.6
  • 62
    • 84880736969 scopus 로고    scopus 로고
    • Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO- 4538)
    • abstr 3016.
    • Grosso J, Horak CE, Inzunza D, Cardona DM, Simon JS, Gupta AK, et al. Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO- 4538). J Clin Oncol 2013;31:abstr 3016.
    • (2013) J Clin Oncol , vol.31
    • Grosso, J.1    Horak, C.E.2    Inzunza, D.3    Cardona, D.M.4    Simon, J.S.5    Gupta, A.K.6
  • 64
    • 4243096258 scopus 로고    scopus 로고
    • B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression
    • Konishi J, Yamazaki K, Azuma M, Kinoshita I, Dosaka-Akita H, Nishimura M. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res 2004;10:5094-5100.
    • (2004) Clin Cancer Res , vol.10 , pp. 5094-5100
    • Konishi, J.1    Yamazaki, K.2    Azuma, M.3    Kinoshita, I.4    Dosaka-Akita, H.5    Nishimura, M.6
  • 65
    • 84904024273 scopus 로고    scopus 로고
    • Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy
    • Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014;20:5064-5074.
    • (2014) Clin Cancer Res , vol.20 , pp. 5064-5074
    • Taube, J.M.1    Klein, A.2    Brahmer, J.R.3    Xu, H.4    Pan, X.5    Kim, J.H.6
  • 67
    • 84937563758 scopus 로고    scopus 로고
    • PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation
    • Ji M, Liu Y, Li Q, Li XD, Zhao WQ, Zhang H, et al. PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation. J Transl Med 2015;13:5.
    • (2015) J Transl Med , vol.13 , pp. 5
    • Ji, M.1    Liu, Y.2    Li, Q.3    Li, X.D.4    Zhao, W.Q.5    Zhang, H.6
  • 68
    • 84937549213 scopus 로고    scopus 로고
    • Recent advances of immunotherapy in lung cancer: anti-programmed cell death-1/programmed death ligand-1 antibodies
    • Yang LL, Wu YL. Recent advances of immunotherapy in lung cancer: anti-programmed cell death-1/programmed death ligand-1 antibodies. Lung Cancer Management 2014;3:175-190.
    • (2014) Lung Cancer Management , vol.3 , pp. 175-190
    • Yang, L.L.1    Wu, Y.L.2
  • 70
    • 84879625854 scopus 로고    scopus 로고
    • New checkpoint inhibitors ride the immunotherapy tsunami
    • Mullard A. New checkpoint inhibitors ride the immunotherapy tsunami. Nat Rev Drug Discov 2013;12:489-492.
    • (2013) Nat Rev Drug Discov , vol.12 , pp. 489-492
    • Mullard, A.1
  • 73
    • 84937579282 scopus 로고    scopus 로고
    • Antibodies that bind to human programmed death ligand 1 (pd-l1)
    • Google Patents
    • Pierce RH, Bourne P, Liang L, Bigler M. Antibodies that bind to human programmed death ligand 1 (pd-l1). Google Patents; 2014: WO 2014100079 A1.
    • (2014)
    • Pierce, R.H.1    Bourne, P.2    Liang, L.3    Bigler, M.4
  • 75
    • 84920937027 scopus 로고    scopus 로고
    • Clinical Activity and Safety of MEDI4736, an Anti-PD-L1 Antibody, in Patients with Head and Neck Cancer
    • Fury M, Ou SH, Balmanoukian A, Hansen A, Massarelli E, Blake-Haskins A, et al. Clinical Activity and Safety of MEDI4736, an Anti-PD-L1 Antibody, in Patients with Head and Neck Cancer. Ann Oncol 2014;25:iv340-iv356.
    • (2014) Ann Oncol , vol.25 , pp. iv340-iv356
    • Fury, M.1    Ou, S.H.2    Balmanoukian, A.3    Hansen, A.4    Massarelli, E.5    Blake-Haskins, A.6
  • 76
    • 84892866206 scopus 로고    scopus 로고
    • Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma
    • Weber JS, Kudchadkar RR, Yu B, Gallenstein D, Horak CE, Inzunza HD, et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol 2013;31:4311-4318.
    • (2013) J Clin Oncol , vol.31 , pp. 4311-4318
    • Weber, J.S.1    Kudchadkar, R.R.2    Yu, B.3    Gallenstein, D.4    Horak, C.E.5    Inzunza, H.D.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.